Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wyeth is now a wholly owned subsidiary of Pfizer
The objectives of the study are to identify doses of PPM-204 that are therapeutically effective and well tolerated in improving glycemic control over 24 weeks of treatment in subjects with type 2 diabetes mellitus (T2DM).
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women of non-childbearing potential, 18 to 70 years old
Subjects currently treated with diet and exercise alone and subjects receiving a single oral antidiabetic medication
BMI \> 23 and \< 43
For subjects currently treated with 1 antidiabetic medication: HbA1c is greater than or equal to 6.8% and less than or equal to 8.5%.
For subjects not currently treated with antidiabetic medications: HbA1c is greater than or equal to 7.2% and less than or equal to 9.0%
You may not be if
Subjects requiring insulin therapy
Subjects currently receiving 2 or more oral antidiabetic medications
Subjects requiring systemic corticosteroids, unless treatment was discontinued at least 4 weeks before the screening visit
Subjects receiving warfarin
Subjects currently receiving thiazolidinediones, unless treatment was discontinued 8 weeks before the screening visit
